Investing.com -- Healthcare often acts as a shelter because people keep buying medicine and care in any economy. The screener (snapshot data, which may lag live prices) points to a few broad, low-cost US funds. Nasdaq-100 funds like Invesco QQQ Trust (QQQ) fell about 9% over 3 months. Healthcare funds gained roughly 10-12% over the same period.
XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.
VHT's 411 holdings and 0.09% expense ratio deliver identical 5-year returns to IYH's concentrated 100-stock portfolio, raising questions about whether lower costs justify broader diversification.
IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.
U.S. healthcare stocks delivered 28.8% gains over one year versus 22.5% for international peers. Both funds carry nearly identical expense ratios and low volatility profiles.
IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.
Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns.
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.
This is the newest page. Registered accounts read further back.